Adela
FOSTER CITY, CA, United States · Biotechnology · 27 employees
Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network’s Princess Margaret Cancer Centre. Adela is initially planning to develop the technolog
Funding history
- Venture - Series Unknown — $5.0M — Apr 2026
- Venture - Series Unknown — $25.4M — Jul 2025
- Venture - Series Unknown — $48.5M — Jul 2024
- Seed — $1.2M — Feb 2024
- Seed — $3.3M — Feb 2024
Recent signals
- Apr 23, 2026: Raised $5.0M in Venture - Series Unknown
- Jul 08, 2025: Raised $25.4M in Venture - Series Unknown
- Jul 29, 2024: Raised $48.5M in Venture - Series Unknown
- Feb 14, 2024: Raised $1.2M in Seed
- Feb 14, 2024: Raised $3.3M in Seed
- Dec 14, 2023: Adela Appoints Precision Medicine Veteran Lisa Alderson as CEO
- Sep 25, 2023: Raised $48.0M in Funding Round
- Aug 11, 2023: Raised $48.5M in Venture - Series Unknown
See plans & pricing → Track Adela ’s funding, hiring, and signals — with verified contacts — on Fundz.